Odyssey Therapeutics, Inc. (ODTX): Results of Operations and Financial Condition
Odyssey Therapeutics, Inc. (ODTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. 8-K false 0001882782 0001882782 2026-06-17 2026-06-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17,
How this was made
The 30-second read
Why it matters
The filing itself is a procedural disclosure that results were announced; the trading-relevant content is in Exhibit 99.1, which is not included in the scraped body.
Market read
This is a confirmation of an earnings release, but without the earnings figures/guidance in the provided text, it offers limited actionable signal.
What to watch
Traders should verify Exhibit 99.1 for: cash/burn rate, net loss trend, any impairment/one-offs, and whether management provided updated operating runway or pipeline timing.
Background
The SEC 8-K (Item 2.02) indicates Odyssey Therapeutics released quarterly financial results for the three months ended March 31, 2026 and furnished the related press release as Exhibit 99.1.
Ticker impact
Odyssey Therapeutics filed an 8-K stating it announced financial results for the three months ended March 31, 2026, with a press release as Exhibit 99.1.
Likely modest/uncertain near-term impact until the Exhibit 99.1 earnings details (revenue, cash, losses, outlook) are reviewed.
The filing confirms results were released, but provides no numbers, comparisons, or forward-looking statements in the provided body.
Market effects
Limited from this text alone; biotech earnings can affect sentiment toward small-cap drug developers, but no sector datapoints are provided.
No regional macro or cross-asset linkages disclosed.
No global regulatory, trial, or partnership updates included in the provided excerpt.
Counterpoint
Because the excerpt omits the actual results and any guidance, the market reaction may be driven by items not captured here (cash runway, pipeline milestones, or outlook).
Key entities
- companyOdyssey Therapeutics, Inc.
Subject of the 8-K; announced financial results for the three months ended March 31, 2026 and furnished a press release as Exhibit 99.1.
- regulatory_filingSEC Form 8-K
Current report used to disclose results of operations and financial condition (Item 2.02).
